Project Grant K08HL168155
Award Date
9/17/24
Completion Date
6/30/29
Dollars Obligated
$169K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is focused on evaluating accessory cells to improve homing and engraftment efficiency of CD34+ cells from sickle cell disease (SCD) patients. The $128,100 award to the New York Blood Center, Inc. aims to address key impediments to equity of access to SCD gene therapy, such as the challenges in collecting an adequate number of hematopoietic...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $827,753.90 to Bloodworks (doing business as Puget Sound Blood Center and Program) to conduct research on oxidative stress and cysteine modification in sickle cell disease. The research aims to investigate how thiol isomerases, a class of oxidoreductase enzymes, promote vaso-occlusion - a major clinical burden in sickle cell...
The federal Project Grant award R21CA299166 for $225,101.00 was issued by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395). The award supports research to investigate the mechanisms underlying the increased risk of hematological malignancy (HM) observed in patients with sickle cell disease (SCD), especially those receiving curative gene therapy or hematopoietic stem cell transplants. The key research objectives are to: 1) perform experiments to study the...
This federal Project Grant award, totaling $608,126.00 and awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop and validate single-cell biomarkers for predicting clinical outcomes in sickle cell disease (SCD). The grant supports research to: Define the relationship between SCD adverse clinical outcomes and single-cell biochemical and mechanical properties to identify promising biomarkers. Define the...
This $765,622 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of orally bioavailable targeted protein degraders to induce fetal hemoglobin (HBF) production for the treatment of sickle cell disease (SCD). The primary awardee, Yale University, will collaborate closely with researchers at the Children's Hospital of Philadelphia on this project. The key objectives are to discover and optimize small...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will provide $252,285 to St. Jude Children's Research Hospital to support a 5-year research training program focused on basic and translational classical hematology. The program will fund three postdoctoral fellows to conduct hypothesis-driven research aimed at elucidating the mechanisms of non-malignant blood diseases and identifying new...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $607,535 to the University of Illinois to investigate the effects of the compound hemin on the pulmonary endothelium and its role in the development of pulmonary complications associated with sickle cell disease. The research aims to evaluate the concentration-dependent effects of hemin on pulmonary artery endothelial cells,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $734,607 to Boston Medical Center Corporation to study the mechanisms regulating the migration of hematopoietic stem cells (HSCs) into the bone marrow niche. The research aims to elucidate the endothelial cell adhesion and endocytosis processes that facilitate the trans-endothelial migration of HSCs, with the goal of developing...
This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports a $1,123,357 research program to investigate the specialized microenvironments within bone marrow that regulate blood cell production. The 7-year project, awarded on January 1, 2025, will focus on three key areas: 1) defining the function of specialized bone marrow microenvironments that serve as niches for different...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,933,142 to support research on the mechanisms behind hematopoietic stem cell (HSC) functional decline after bone marrow transplantation. The key objectives are to understand why abnormal mitochondria accumulate in HSCs and the impact on HSC metabolism and function, with the goal of identifying potential interventions to...